Brisbane, CA — September 27, 2022
It has been an exciting journey for the Cureline Group, from the time CEO Dr. Olga Potapova spearheaded the establishment of the company in 2003, up to where it is today. In preparing for the company’s 20th anniversary in 2023, the key members of Cureline Group gathered in Turkey for a management conference in order to review and evaluate the business performance of the growing organization, introduce new initiatives and have quality time together.
The objectives of the meeting were to further strengthen relationships, foster trust and camaraderie among partners and team members from all over the world, develop marketing strategies that would improve client relationships, and explore opportunities and plans for growth and expansion. Dr. Potapova facilitated the exchange of ideas and took the time to map out the directions of Cureline’s global operations moving forward.
Lively discussions among team representatives from our offices in the USA, the EU, Central Europe, South America, Turkey, India, Central and South Pacific Asia underscored the importance of cohesiveness across all units and to embrace the significance of working with the company ethos in mind: As a team, nothing is impossible. Together, we can bring Cureline to even greater heights, and in the process make a difference in the lives of more and more people, globally.
From its origins as a human biospecimen biorepository in the San Francisco Bay area and growing into a Translational and Precision Medicine global CRO, the Cureline Group now counts over 800 clients worldwide, with international clinical network operations in more than 150 centers across 20 countries. With this increased international presence, and with the global human biologic samples market projected to reach $10.4 billion in 2030, we believe our company is strategically poised to continue expanding its role as a key provider of quality human biospecimens (HBS), highly-specialized HBS biobanking, analysis and processing, histology and molecular services, and other translational research needs. We remain focused on the pursuit of capacity building initiatives, particularly in the field of good manufacturing practices in advanced therapy medicinal products (ATMP) for the near future. We look forward to more collaborative opportunities in 2023, and increasing quality output that would bring our clients closer to their goals.
All in all, our Turkey conference proved to be the perfect venue to look at how far the Cureline Group has come, and how much potential the future holds. We look forward to increasing quality output and collaborative opportunities in 2023!
For more information, contact +1 415 468 6400